High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Published Date: 10 Jan 2025

ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

2.

AI catches one-third of interval breast cancers missed at screening

3.

Never in a million years did I think I'd have to limit my chemotherapy.

4.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

5.

Novel probes to label macrophages associated with cancer progression using a selective dye


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot